Brought to you by 
Lilly and Jubilant form JV; Jubilant later takes over
Oct 2008
Executive Summary
Eli Lilly and Jubilant Organosys (drug discovery, research, and manufacturing services; based in India) have agreed to form a 50/50 joint venture for the development of new drugs across various therapy areas.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Joint Venture
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lilly and Jubilant form JV; Jubilant later takes over
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice